Valeant Pharmaceuticals International, Inc.
GPTKB entity
Statements (28)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:acquisition |
gptkb:Obagi_Medical_Products
gptkb:Meda_AB gptkb:Aton_Pharma gptkb:Salix_Pharmaceuticals gptkb:Bausch_+_Lomb gptkb:Ortho_Dermatologics gptkb:iNova_Pharmaceuticals gptkb:Dermik_Laboratories gptkb:Aqua_Pharmaceuticals CeraVe Sientra Dendreon Sandoz's_generic_business Synergetics_USA |
gptkbp:CEO |
gptkb:Joseph_C._Papa
|
gptkbp:founded |
1960
|
gptkbp:headquarters |
gptkb:Laval,_Quebec,_Canada
|
https://www.w3.org/2000/01/rdf-schema#label |
Valeant Pharmaceuticals International, Inc.
|
gptkbp:industry |
pharmaceuticals
|
gptkbp:keyPeople |
gptkb:Robert_A._Ingram
|
gptkbp:previousName |
gptkb:Valeant_Pharmaceuticals
|
gptkbp:products |
branded pharmaceuticals
|
gptkbp:revenue |
$8.4 billion (2015)
|
gptkbp:stockSymbol |
VRX
|
gptkbp:subsidiary |
gptkb:Bausch_Health_Companies_Inc.
|
gptkbp:type |
public company
|
gptkbp:website |
www.valeant.com
|